

BX-795, Dual TBK1/IKKε inhibitor – enhances lentiviral transduction efficiency

Catalog	Unit
TBI4677-5MG	5 mg
TBI4677-25MG	25 mg

Product Details

Formal Name: N-[3-[[5-Iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-

yl]amino]phenyl]pyrrolidine-1-carboxamide

Molecular Formula: C23H26IN7O2S


Formula Weight: 591.47 **CAS Number:** 702675-74-9

Purity: >97%

Formulation: powder

Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Storage: -20° C **Stability:** ≥ 2 years.



Applications

Dual TBK1/IKKε inhibitor – enhances lentiviral transduction efficiency

Functions

BX795, originally described as a moderately potent inhibitor of PDK1 (IC50 = 111 nM), is, more importantly, a dual inhibitor of TBK1 and IKK ϵ (IC50's = 6 and 41 nM respectively). TBK1 and IKK ϵ regulate the production of Type I interferons during bacterial and viral infection via phosphorylation of the transcription factor IRF. It also inhibited of MARK, MLK, NUAK, AurB, and ERK8.3 BX795 exhibited antitumor activity in human oral squamous cell carcinoma, pancreatic ductal adenocarcinoma, and Glioblastoma Multiforme. BX795 has been used to enhance lentiviral transduction efficiency in human NK cells and human primary T cells for CAR-T cell therapy.

Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.